Neck injection boosts PTSD therapy? new study investigates
NCT ID NCT05534126
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding a stellate ganglion block (a numbing injection in the neck) to cognitive processing therapy (a type of talk therapy) helps reduce PTSD and chronic pain more than therapy alone. Sixty adults with PTSD took part. The goal was to see if the combination improves symptoms better than therapy with a placebo injection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Nov 2022
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Are 18 years or older 2. Are fluent in English 3. Reside in Illinois 4. Have safe transportation means other than driving themselves to Rush University Medical Center for two separate procedures (e.g., Uber, family or friend to drive them to study visits, etc.) 5. Have experienced a Criterion A traumatic event during their lifetime 6. Have a PTSD diagnosis verified via the Clinician Administered PTSD Scale for DSM-5 7. Have not previously received stellate ganglion blocks 8. Are willing and able to participate in daily Cognitive Processing Therapy over the course of one week 9. Are willing and able to complete self-report measures and clinician-rated assessments at multiple time points over the course of the study Exclusion Criteria: 1. The traumatic event occurred in the past month 2. They are currently suicidal or homicidal (i.e., plan and intent) 3. They have unmanaged psychosis or mania 4. They have not been on a stable dose of psychotropic medication for at least one month by the time of the baseline assessment or are planning to change their medications within 3 months of starting their participation in the study 5. They have completed an evidence-based cognitive behavioral PTSD treatment (e.g., Cognitive Processing Therapy or Prolonged Exposure) in the past 12 months or are currently receiving an evidence-based PTSD treatment 6. They have an intellectual disability or significant cognitive impairment that would prevent them from engaging in CPT, as assessed via the Mini-Mental State Exam-Second Edition (MMSE-2) 7. They are currently on any blood-thinning medications or have a coagulopathy 8. They have any of the following conditions: a recent myocardial infarction, glaucoma, a pre-existing contralateral nerve palsy, severe emphysema or a cardiac conduction blockade. 9. They are allergic to any of the medications injected (i.e., ropivacaine, lidocaine, propofol, medications) 10. They have an active infection 11. They have a serious or unstable medical illness or instability for which hospitalization may be likely within the next year 12. They have a visual or auditory impairment that would prevent them from fully participating in study activities 13. They are involved with current legal actions related to the traumatic event that is anticipated to be targeted during treatment 14. Subjects who, at the time of consent, appear to have extenuating life circumstances (e.g., unstable housing, no internet access, etc.) which, in the judgement of the Principal Investigator, could affect the ability to deliver the intervention with fidelity
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic pain are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One 2-Hour class may help new mothers manage Post-Cesarean pain
- Can AI decode how trauma therapy heals?
- Zapping deep brain regions to quiet chronic back pain
- Herbal injections at acupuncture points tested against physical therapy for Long-Lasting sciatica
- Can difficulty naming emotions shape how much tailbone pain you feel?
- Can talk therapy rewire the brain to ease burn Survivors' pain?